News
AstraZeneca to withdraw Nasdaq listings ahead of NYSE direct listing
The move follows AstraZeneca’s previously announced plan to complete a direct listing of its Ordinary Shares and debt securities on the New York Stock Exchange
- By IPP Bureau
| January 21, 2026
AstraZeneca has announced that it will voluntarily withdraw its American Depositary Shares (ADSs) and debt securities from The Nasdaq Stock Market.
The move follows AstraZeneca’s previously announced plan to complete a direct listing of its Ordinary Shares and debt securities on the New York Stock Exchange, effective after market close on 30 January 2026.
As part of its shareholder-approved strategy to harmonise its share listing structure, AstraZeneca said the change is designed “to deliver a global listing for global investors in a global company.”
“Following implementation of the Harmonised Listing Structure, shareholders will be able to trade their interests in the Ordinary Shares across the London Stock Exchange, Nasdaq Stockholm and the NYSE,” the company said.
Trading of the ADSs and debt securities on Nasdaq is expected to end on 30 January, with Ordinary Shares and debt securities set to begin trading on the NYSE from Monday, 2 February 2026. AstraZeneca confirmed the Ordinary Shares will continue under the ticker symbol AZN.
